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Earlier and more frequent
diagnosis of multiple sclerosis
using the McDonald criteria
The McDonald criteria allow multiple
sclerosis (MS) to be diagnosed in patients
with a clinically isolated syndrome (CIS)
who have MRI evidence of dissemination
in time and space.1–3 There have been
successive versions of the criteria in
2001,1 20052 and 20103 with different
requirements for dissemination in time
and space. Although each version has
been shown to have a high sensitivity and
speciﬁcity for the development of
clinically-deﬁnite MS (CDMS), few
studies have investigated how much
sooner4 and how more often5 MS can be
diagnosed in patients with CIS using the
McDonald criteria.
We recruited 178 patients with CIS pre-
senting to Moorﬁelds Eye Hospital and
the National Hospital for Neurology and
Neurosurgery between 1995 and 2004.
The study was approved by ethics com-
mittees at both hospitals. Patients were
seen at baseline, then for follow-up after
3 months, 1 year, 3 years and 6 years. At
each study visit informed consent was
obtained. Patients were assessed with a
detailed review of neurological symptoms
and neurological examination. Relapses
were recorded at study visits, but patients
were also encouraged to contact the
research team at the time of new neuro-
logical symptoms. MRI of the brain and
whole spine was obtained at each visit on
the same 1.5 T Signa scanner, as described
elsewhere.6 Each scan was reviewed by a
neuroradiologist blinded to the patient’s
clinical status. The number, location and
activity (ie, gadolinium enhancement) of
T2 lesions was recorded.
During follow-up CDMS was deﬁned
according to Poser criteria. The
McDonald criteria were applied retro-
spectively and MS diagnosed when MRI
criteria for dissemination in time/space
were met or at the time of a second clin-
ical attack, whichever occurred ﬁrst.1–3
Only patients with at least one follow-up
MRI and at least 36 months of clinical
follow-up were included in this analysis.
Comparison of within-patient times to
MS diagnosis by each diagnostic criterion
used the non-parametric one-sample
Wilcoxon signed-rank test, since time dif-
ferences were skewed. Proportions of
diagnoses by the different criteria in the
same patients were compared using
McNemar’s test for paired proportions
(exact form). Analyses were carried out in
Stata 13.1 (Stata Corporation, College
Station, Texas, USA). Statistical signiﬁ-
cance is reported at p<0.05.
One hundred and ﬁfty-seven patients
(mean age 32.4 years, 64% female) had
sufﬁcient clinical and MRI follow-up to
be included in this analysis. CIS locations
were optic neuritis in 128, brainstem 18,
spinal cord 10 and hemispheric 1. Mean
follow-up was 5.8 years (range 3.0–
11.9 years). One patient was treated with
disease-modifying therapy prior to devel-
oping CDMS.
Seventy-one (45%) patients were classi-
ﬁed as CDMS, 69 after a second clinical
attack and two developed secondary pro-
gressive MS following a CIS. Figure 1
shows Kaplan-Meier curves for the time
to diagnosis of MS using the Poser and
McDonald criteria for patients with CIS
who developed CDMS. Mean time to
CDMS was 23.1 months compared with
12.0, 10.5 and 6.2 months using the
2001, 2005 and 2010 McDonald criteria
(p<0.0001 for comparisons with time to
CDMS).
Of 86 (55%) who did not have a
second attack, 24 (28%), 26 (30%) and
36 (42%) satisﬁed 2001, 2005 and 2010
McDonald criteria with MRI evidence of
dissemination in time and space
(MRI-only MS). Signiﬁcantly more
patients with CIS had MRI-only MS
when applying the 2010 criteria, com-
pared with the 2001 (p=0.0002) and
2005 criteria (p=0.001). Most patients
with MRI-only MS satisﬁed the MRI cri-
teria in the ﬁrst year after CIS; 18 (75%),
18 (69%) and 26 (75%) patients using the
2001, 2005 and 2010 criteria respectively.
When all 157 patients with CIS were
considered together, 71 (45%) had
CDMS, 36 (23%) had MRI-only MS and
50 (32%) did not have MS using the
2010 McDonald criteria after 6 years.
Establishing a diagnosis of MS at an
earlier time point provides an explanation
for worrying symptoms and allows for
timely discussions about the nature of MS
and its management, including use of
disease-modifying treatments. In this large
CIS cohort, MS was diagnosed signiﬁ-
cantly earlier using the McDonald criteria.
The time gain with each revision of the
criteria reﬂects the less stringent
Figure 1 Kaplan-Meier survival curve showing time to diagnosis of multiple sclerosis (MS) using
Poser and McDonald criteria among patients with clinically isolated syndrome who developed
clinically-deﬁnite MS.
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requirements for dissemination in time
and space, while retaining high speciﬁ-
city.1–3 Among patients with CIS in this
study who ultimately developed CDMS,
the mean time to diagnosis of MS halved
from 12 months with the 2001 criteria to
6.2 months with the 2010 criteria, a time
gain of 16.9 months compared with mean
time to CDMS. The time gain using the
McDonald criteria was signiﬁcantly
greater in this study than in a previous
hospital-based series.4 However, in that
study spinal imaging was not performed
and not all patients had postcontrast
T1-weighted scans or follow-up MRI,
both important for demonstrating dissem-
ination in time.
The McDonald criteria identify a sig-
niﬁcant number of patients with CIS with
MRI evidence of dissemination of time
and space in the absence of further clinical
events,5 and the number has increased as
the criteria have been revised. These
patients probably have a form of MS that
remains largely subclinical. Given the rela-
tively high frequency of MRI-only MS
(almost a third of those diagnosed using
the 2010 criteria), the possibility arises
that the new diagnostic criteria are identi-
fying a milder form of MS than in the
past when the diagnosis was based on
clinical course alone. There is the poten-
tial for the natural history of relapse-onset
MS to be being favourably modiﬁed by
changes to the diagnostic criteria, inde-
pendent of any effect of disease-
modifying treatments.7 These issues are
important when counselling patients with
CIS about prognosis and in deciding
whether to initiate treatment.
One potential limitation of our study is
an over-representation of patients with
optic neuritis, which may have a more
benign prognosis that other CIS types.8
However, almost 80% of patients with
optic neuritis had baseline MRI abnormal-
ities, indicating a group at high-risk for
developing MS.
In conclusion, the McDonald criteria
allow MS to be diagnosed sooner and
more often in patients with CIS. While
the McDonald criteria facilitate an earlier
diagnosis of MS, up to a third of patients
with CIS who satisfy the 2010 criteria do
not have further clinical events, at least in
the medium-term.
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